Repository logo
 
Publication

Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era.

2025-01-28Review Open access
Simple item page
dc.contributor.authorLapão, Tânia
dc.contributor.authorBarata, Rui
dc.contributor.authorJorge, Cristina
dc.contributor.authorFlores, Carlos
dc.contributor.authorCalado, Joaquim
dc.date.accessioned2025-09-26T15:34:51Z
dc.date.available2025-09-26T15:34:51Z
dc.date.issued2025-01-28
dc.description.abstractWith the approval of tolvaptan as the first specific medicine for the treatment of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD), biomarker discovery has gained renewed interest as it is widely recognized that these will be crucial in clinical decision-making, serving as either prognostic or predictive tools. Since the marketing authorization was first issued in 2015 for ADPKD, tolvaptan has remained the sole pharmacological compound specifically targeting the disease. For ADPKD patients it is an invaluable medicine for retarding disease progression. Although the field of overall biomarker discovery and validation has been detailed in several publications, the role of inflammation remains largely overlooked in ADPKD. The current work aims to provide the reader with an updated review of inflammation biomarkers research in ADPKD, highlighting the role of urinary MCP-1 (monocyte chemoattractant protein-1) as the most promising tool.eng
dc.identifier.citationInt J Mol Sci . 2025 Jan 28;26(3):1121. doi: 10.3390/ijms26031121.
dc.identifier.doi10.3390/ijms26031121.
dc.identifier.pmid39940890
dc.identifier.urihttp://hdl.handle.net/10400.17/5185
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAnimals
dc.subjectHumans
dc.subjectHSJ PAT CLIN
dc.subjectHCC NEF
dc.subjectAntidiuretic Hormone Receptor Antagonists* / therapeutic use
dc.subjectBiomarkers* / urine
dc.subjectChemokine CCL2 / urine
dc.subjectInflammation* / metabolism
dc.subjectPolycystic Kidney
dc.subjectAutosomal Dominant* / metabolism
dc.subjectAutosomal Dominant* / drug therapy
dc.subjectAutosomal Dominant* / urine
dc.subjectTolvaptan* / therapeutic use
dc.titleAutosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era.eng
dc.typereview
dspace.entity.typePublication
oaire.citation.issue3
oaire.citation.startPage1121
oaire.citation.titleInternational Journal of Molecular Sciences
oaire.citation.volume26
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMSci.pdf
Size:
865.43 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

PAT CLIN - Artigos
NEF - Artigos